- Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
- Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
- Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
- Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
- Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology
Can Fite Biopharma Ltd (CF5B:STU) closed at 0.75, 10.29% above the 52 week low of 0.68 set on Oct 04, 2022.
0.68Oct 04 20222.08Dec 20 2021
Data delayed at least 15 minutes, as of Dec 02 2022.